Neurogenic Small Molecules Reverse miR-342-3p-Mediated Tumorigenesis in Renal Cell Carcinoma

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Cigarette smoking is a known risk factor for clear cell renal cell carcinoma (ccRCC).
• The molecular mechanisms linking smoking to ccRCC development are not fully understood.
• This study investigates the role of miR-342-3p and miR-342-5p in ccRCC, particularly in relation to smoking status.

Purpose of the Study:

• To determine if smoking status affects the expression of miR-342-3p and miR-342-5p in ccRCC tissues and plasma.
• To identify the functional targets of miR-342-3p in ccRCC.
• To explore the potential therapeutic effects of neurogenic small molecules in ccRCC.

Main Methods:

• Quantitative reverse transcription polymerase chain reaction (qRT-PCR) was used to measure miR-342-3p and miR-342-5p expression in ccRCC tissues and plasma from patients and controls.
• Bioinformatic analyses (miRTARGET, DAVID Gene Ontology) were performed to identify miR-342-3p targets.
• Cell proliferation assays (Cell Counting Kit-8) were conducted using 293T and 786-O cells treated with miR-342-3p mimics and neurogenic small molecules.

Main Results:

• Both miR-342-3p and miR-342-5p were significantly upregulated in ccRCC tissues and plasma.
• miR-342-3p expression positively correlated with smoking status, being highest in current smokers.
• Plasma levels of miR-342-3p and miR-342-5p showed potential as diagnostic biomarkers for ccRCC (AUC=0.767).
• miR-342-3p targets were enriched in lipid metabolism and neurogenesis pathways.
• Overexpression of miR-342-3p promoted cell proliferation, an effect attenuated by neurogenic small molecules.

Conclusions:

• Cigarette smoking upregulates miR-342-3p and miR-342-5p in ccRCC.
• miR-342-3p promotes ccRCC tumorigenesis by suppressing neurogenic genes.
• Neurogenic small molecules may represent a therapeutic strategy to counteract ccRCC progression by inhibiting miR-342-3p's effects.